Özet:

The aim of this study is to analyze the cases of drug-related osteonekrosis (MRONJ) in the literature in the past five years; the factors that differ from the drug or drug that is identified as the cause of osteonekrosis, the systemic or local factors that contribute to the development of osteonekrosis, the methods of imaging used in these cases, the treatment options. Tools and Methods: 113 presentations of facts in the literature related to MRONJ were studied between 2013-2018. Literary research was conducted through PubMed. The patient’s age, gender, systemic illness, data of past dental procedures, the localization of osteonekrosis injury, the symptoms observed in the patient, the methods of imaging used in the diagnosis, preferred treatment options, the post-treatment presentations of the facts were studied in terms of whether or not it was null. The average age of patients in the presentations of the study was 66.7 ± 12.28. In cases, MRONJ was found to be mostly observed in women (62.8 percent). The risk factor that plays a role in the formation of osteonecrosis were drugs (55%, excess methotrexate). As a cause of the use of the drug that causes osteonecrosis, many (67.1%) cancers were detected. MRONJ was the drug denosumab identified in non-bifosphanate drugs (18.3%). In 63.5 percent of patients had a history of pre-osteonecrosis dental treatment. In cases, 68.9% of osteonecrosis occurred in the mandibula. The symptom identified in patients was pain (65.7 per cent). In all of the cases examined, conservative therapy was used, with 69 patients (62.7%) in addition to surgical therapy and 9 patients in laser therapy. The result: Although MRONJ is often associated with the use of bifosphonate, it may also be caused by antianeoplastic drugs used for cancer and some drugs used for systemic diseases such as rheumatoid arthritis.  Due to the excessive variety of medications that cause osteonecrosis, the question of the medications used or to be used in the systemic conditions of patients is important in the prevention and diagnosis of osteonecrosis. Keywords: Osteonecrosis, Bifosphonate and Metotrexate.

Anahtar Kelimeler: